Shareholders' Equity (Tables)

12 Months Ended

Dec. 31, 2021

Schedule of Balance Of Non-controlling Interests

The net change in the balance of our four non-controlling interests for the years ended December 31, 2021 and 2020 is as follows (in thousands):


	RPSFT		Legacy Investors Partnerships		Continuing Investors Partnerships (1)		EPA Holdings		Total
December 31, 2019	$	35,883	$	—	$	—	$	—	$	35,883
Contributions	—		1,165,258		9,418		—		1,174,676
Transfer of interests	—		1,037,161		—		—		1,037,161
Distributions	(112,339)		(594,592)		(85,426)		—		(792,357)
Net Income prior to IPO	42,151		102,892		—		—		145,043
Effect of exchange by Continuing Investors of Class B ordinary shares for Class A ordinary shares and reallocation of historical equity	—		(750)		2,433,848		—		2,433,098
Issuance of Class A ordinary shares sold in IPO, net of offering costs	—		—		758,354		—		758,354
Other exchanges	—		—		(309,566)		—		(309,566)
Net income subsequent to IPO	46,741		218,137		316,993		—		581,871
Other comprehensive income/(loss):
Unrealized gains on available for sale debt securities	—		15,015		7,488		—		22,503
Reclassification of unrealized losses on available for sale debt securities	—		(3,612)		(6,018)		—		(9,630)
December 31, 2020	$	12,436	$	1,939,509	$	3,125,091	$	—	$	5,077,036

(1) Related to the Continuing Investors Partnerships’ ownership of approximately 36% in RP Holdings through their ownership of the RP Holdings Class B Interests as of December 31, 2020. Royalty Pharma plc owns the remaining 64% of RP Holdings through its ownership of RP Holdings Class A Interests and Class B Interests as of December 31, 2020.


	RPSFT		Legacy Investors Partnerships		Continuing Investors Partnerships (1)		EPA Holdings		Total
December 31, 2020	$	12,436	$	1,939,509	$	3,125,091	$	—	$	5,077,036
Contributions	—		35,148		13,391		—		48,539
Distributions	(56,490)		(425,050)		(133,433)		—		(614,973)
Other exchanges	—		—		(642,974)		—		(642,974)
Net Income	57,582		266,570		297,321		—		621,473
Other comprehensive income/(loss):
Unrealized gains on available for sale debt securities	—		2,038		3,227		—		5,265
Reclassification of unrealized losses on available for sale debt securities	—		(8,946)		(13,469)		—		(22,415)
December 31, 2021	$	13,528	$	1,809,269	$	2,649,154	$	—	$	4,471,951

(1) Related to the Continuing Investors Partnerships’ ownership of approximately 29% in RP Holdings through their ownership of the RP Holdings Class B Interests as of December 31, 2021. Royalty Pharma plc owns the remaining 71% of RP Holdings through its ownership of RP Holdings Class A Interests and Class B Interests as of December 31, 2021.